Akero Therapeutics Stock News

Akero Therapeutics (NASDAQ:AKRO) had its price target raised by equities researchers at Canaccord Genuity from $46.00 to $49.00 in a research report issued on Monday, The Fly reports. The brokerage presently has a buy rating on the stock. Canaccord Genuitys target price would suggest a potential upside of 95.77% from the stocks previous close. Several []

Related Stocks: PINS , GMF , MINT , IWD , VGT , FEZ , COMP , AKRO , FVRR , ACVA , JEPI , CWI , AIA , BYRN , CSTM , OIH , SAVE , TBT ,

Akero Therapeutics (NASDAQ:AKRO) had its price objective raised by Morgan Stanley from $27.00 to $29.00 in a research report report published on Monday morning, Analyst Ratings Network reports. The firm currently has an equal weight rating on the stock. Several other equities research analysts have also recently weighed in on AKRO. HC Wainwright lowered their []

Akero Therapeutics (NASDAQ:AKRO) released its quarterly earnings data on Thursday. The company reported ($0.70) earnings per share for the quarter, beating analysts consensus estimates of ($0.91) by $0.21, MarketWatch Earnings reports. Shares of AKRO traded up $0.53 during trading hours on Friday, hitting $25.33. The companys stock had a trading volume of 82,104 shares, compared []

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta

Akero: Ticking All The Right Boxes In NASH

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoh

Akero Therapeutics Inc (NASDAQ: AKRO) has announced full results of the main portion of its Phase 2a BALANCED trial of efruxifermin (EFX) in NASH patients with F1-F3 fibrosis have been published in

Efruxifermin (EFX) also improved markers of liver injury, inflammation, lipoproteins, and glycemic control Efruxifermin (EFX) also improved markers of liver injury, inflammation, lipoproteins, and gly

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoho

Akero Therapeutics Inc (NASDAQ: AKRO) has announced additional analyses from its Phase 2a BALANCED study of efruxifermin (EFX) in non-alcoholic steatohepatitis (NASH) patients with F1-F3 fibrosis.

Analyses also Show that Combining a Threshold for ALT Reduction of ≥17 U/L with Normalization of Liver Fat Improves Predictive Power for Resolution of NASH with 1-Stage Improvement of Fibrosis Analy

Akero Therapeutics (AKRO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepat

Akero Therapeutics: A NASH Pureplay With Differentiated Mid Stage Data